Arbutus Biopharma Corporation (ABUS)

NASDAQ: ABUS · IEX Real-Time Price · USD
1.93
-0.06 (-3.02%)
At close: Sep 22, 2023, 4:00 PM
1.94
+0.01 (0.57%)
After-hours: Sep 22, 2023, 5:00 PM EDT
-3.02%
Market Cap 323.38M
Revenue (ttm) 23.54M
Net Income (ttm) -72.93M
Shares Out 167.56M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,127,650
Open 1.97
Previous Close 1.99
Day's Range 1.88 - 1.97
52-Week Range 1.85 - 3.15
Beta 2.13
Analysts Strong Buy
Price Target 6.00 (+210.88%)
Earnings Date Nov 8, 2023

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO William H. Collier
Employees 96
Stock Exchange NASDAQ
Ticker Symbol ABUS
Full Company Profile

Financial Performance

In 2022, ABUS's revenue was $39.02 million, an increase of 255.11% compared to the previous year's $10.99 million. Losses were -$69.46 million, -21.42% less than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 210.88% from the latest price.

Price Target
$6.0
(210.88% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor

12 days ago - GlobeNewsWire

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove...

16 days ago - GlobeNewsWire

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter

7 weeks ago - GlobeNewsWire

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

2 months ago - GlobeNewsWire

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...

2 months ago - GlobeNewsWire

Arbutus Appoints Two New Executives

Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharm...

2 months ago - GlobeNewsWire

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: A...

3 months ago - GlobeNewsWire

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the ...

3 months ago - GlobeNewsWire

Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023

WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

3 months ago - GlobeNewsWire

Arbutus to Present at Jefferies Healthcare Conference

WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such investors are ad...

4 months ago - PRNewsWire

Arbutus to Present at JMP Securities Life Sciences Conference

WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...

4 months ago - GlobeNewsWire

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023

5 months ago - GlobeNewsWire

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post-  AB-729 treatment

5 months ago - GlobeNewsWire

Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor

WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virol...

5 months ago - GlobeNewsWire

Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove...

5 months ago - GlobeNewsWire

Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023

Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical compa...

5 months ago - GlobeNewsWire

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech

Companies seek compensation for Pfizer's and BioNTech's unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines

6 months ago - GlobeNewsWire

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

Initial data expected in the second half of 2023

6 months ago - GlobeNewsWire

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses

6 months ago - GlobeNewsWire

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

Significant progress made advancing proprietary programs in chronic HBV and Coronavirus

7 months ago - GlobeNewsWire

Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

7 months ago - GlobeNewsWire

Arbutus to Participate in Three Upcoming Investor Conferences

WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

8 months ago - GlobeNewsWire

Arbutus Announces Resignation of Board Member

WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

8 months ago - GlobeNewsWire

Arbutus Announces 2023 Corporate Objectives and Provides Financial Update

Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023

9 months ago - GlobeNewsWire